Abstract:Purposes: As the most abundant epigenetic modification on mRNAs and long non-coding RNAs, N6-methyladenosine (m6A) extensively exists in mammalian cells. Controlled by writers (methyltransferases), readers (signal transducers) and erasers (demethylases), m6A influences mRNA structure, maturation and stability, thus regulating protein expression in a post-transcriptional manner. Nevertheless, current understandings to m6A’s pathological roles in tumorigenesis, especially in gastric cancer (GC) remain to be unveiled. In this study, by incorporating multiple datasets and in vitro experiments, we assessed m6A’s clinical-pathological relevance to GC and explored the underlying mechanisms. Methods: The protein and mRNA expressions of canonical m6A regulators (METTL3/METTL14 as writers, YTHDF1/YTHDF2/YTHDF3 as readers and ALKBH5/FTO as erasers) were merged as signatures to indicate levels of m6A modification. Changes of clinical variables, mutations and molecules were assessed in patients with different m6A indications. Pathway and phenotype changes predicted to be affected by m6A were assessed in vitro with gastric cancer HGC27 and MG803 cell lines. Results: We discovered that writers and readers were potential tumor suppressive, while erasers were potential oncogenic factors in GC. Low-m6A modification was an indication for adverse clinical outcomes and was correlated with specific cancer driving mutations, including CDH1, AR and GLI3. Oncogenic signaling and phenotypes were selectively enriched in m6A groups. Through in vitro experiments, we proved that reduced m6A (represented by METTL14 knockdown) promoted GC proliferation and invasiveness potentially through activating Wnt and PI3K-Akt signaling, while restored m6A (represented by FTO knockdown) reversed these phenotypical and molecular changes. Conclusions: Our work demonstrated that m6A is a potential prognostic predictor in gastric cancer and further reveals the reduction of m6A activates oncogenic signaling and promotes gastric cancer malignancy. Citation Format: Cheng Zhang, Mengqi Zhang, Sai Ge, Xiaotin Lin, Wenwen Huang, Ying Gan, Jing Gao, Lin Shen. Reduced m6A modification predicts malignant phenotypes and augmented tumorigenic signaling in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4314.

Abstract 4330: Pan-cancer Analysis Reveals M6a Modification is Functionally Important in Cancer

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

The emerging roles of N6-methyladenosine RNA methylation in human cancers

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types

Link Between M6a Modification and Cancers

Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers

Pan-cancer Analysis Reveals m6A Variation and Cell-specific Regulatory Network in Different Cancer Types

Characterization of Modification Patterns, Biological Function, Clinical Implication, and Immune Microenvironment Association of m6A Regulators in Pancreatic Cancer

The role of m6A RNA methylation in human cancer

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

Interplay of RNA m6A Modification-Related Geneset in Pan-Cancer

Abstract 4314: Reduced m6A modification predicts malignant phenotypes and augmented tumorigenic signaling in gastric cancer

N6-methyladenosine (m6a) RNA Modification in Tumor Immunity

Epigenetic modification of m6A regulator proteins in cancer

Role of N6-methyladenosine RNA modification in cancer

N6-methyladenosine links RNA metabolism to cancer progression

Transcriptional regulatory networks mediated by abnormal m6A modifications in tumor development

N6-methyladenosine modification participates in neoplastic immunoregulation and tumorigenesis

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

Links Between N6-Methyladenosine and Tumor Microenvironments in Colorectal Cancer